Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: A cross-sectional study

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Petrica, Ligia ^a,b   Vlad, Adrian ^a,b   Gluhovschi, Gheorghe ^a,b   Gadalean, Florica ^a,b   Dumitrascu, Victor ^a,b   Gluhovschi, Cristina ^a,b   Velciov, Silvia ^a,b   Bob, Flaviu ^a,b   Vlad, Daliborca ^a,b   Popescu, Roxana ^a,b   Milas, Oana ^b   Ursoniu, Sorin ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Department of Diabetes and Metabolic Diseases   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ALPHA 1 MICROGLOBULIN; CREATININE; CYSTATIN C; KIDNEY INJURY MOLECULE 1; NEPHRIN; VASCULOTROPIN; BIOLOGICAL MARKER; HAVCR1 PROTEIN, HUMAN; MEMBRANE PROTEIN; VASCULOTROPIN A; VIRUS RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY PROXIMAL TUBULE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROXIMAL TUBULE DYSFUNCTION; TUBULAR DYSFUNCTION; ALBUMINURIA; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FANCONI SYNDROME; METABOLISM; PATHOLOGY; PODOCYTE; URINE;

ALBUMINURIA; BIOMARKERS; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FANCONI SYNDROME; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; PODOCYTES; RECEPTORS, VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84911935623     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112538     Document Type: Article

References (36)

1. US Renal Data System (2008) USRDS 2008 Annual Data Report. Available: http://www.usrds.org. Accessed 11 February 2014.
2. Schernthaner G (2011) Kidney disease in diabetology: lessons from 2010. Nephrol Dial Transplant 26: 454-457.
3. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, et al. (2004) Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27: 195-200.
4. Jefferson JA, Shankland SJ, Pichler RH (2008) Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 74: 22-36.
5. Nakagawa T, Tanabe K, Croker BP, Johnson RJ, Grant MB, et al. (2011) Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol 7: 36-44.
6. Fioretto P, Mauer M (2007) Histopathology of diabetic nephropathy. Semin Nephrol 27: 195-207.
7. Pätäri A, Forsblom C, Havana M, Taipale H, Groop PH, et al. (2003) Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes 52: 2969-2974.
8. Ng DPK, Tai BC, Tan E, Leong H, Nurbaya S, et al. (2011) Nephrinuria associates with multiple renal traits in type 2 diabetes. Nephrol Dial Transplant 26: 2508-2514.
9. Jim B, Ghanta M, Qipo A, Fan Y, Chuang PY, et al. (2012) Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study. PLoS One 7(5): e36041.
10. Ziyadeh FN, Wolf G (2008) Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4: 39-45.
11. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, et al. (2003) Glomerularspecific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716.
12. Kim NH, Kim KB, Kim DL, Kim SG, Choi KM, et al. (2004) Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type 2 diabetes mellitus. Diabet Med 21: 545-551.
13. Comper WD, Haraldsson B, Deen WM (2008) Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 19: 427-432.
14. Russo LM, Sandoval RM, Campos SB, Molitoris BA, Comper WD, et al. (2009) Impaired tubular uptake explains albuminuria in early diabetic nepropathy. J Am Soc Nephrol 20: 489-494.
15. Petrica L, Petrica M, Vlad A, Jianu DC, Gluhovschi G, et al. (2011) Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional study. Nephron Clin Pract 118: c155-c164.
16. Petrica L, Petrica M, Vlad A, Jianu DC, Gluhovschi G, et al. (2009) Nephroand neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr 121: 765-775.
17. Petrica L, Vlad A, Petrica M, Jianu CD, Gluhovschi G, et al. (2011) Pioglitazone delays proximal tubule dysfunction and improves cerebral vessels endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 94: 22-32.
18. Tang SC, Leung JC, Lai KN (2011) Diabetic tubulopathy: an emerging entity. Contrib Nephrol 170: 124-134.
19. (2013) KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease Kidney Int (Suppl) 3: 1-150.
20. Ozdemir AM, Hopfer U, Erhard P, Monnier VM, Weiss MF (2005) Processing advanced glycation end product-modified albumin by the renal proximal tubule and the early pathogenesis of diabetic nephropathy. Ann N Y Acad Sci 1043: 625-636.
21. Kern EF, Erhard P, Sun W, Gennth S, Weiss MF (2010) Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis 55: 824-834.
22. Hong CY, Hughes K, Chia KS, Ng V, Ling SL (2003) Urinary alpha1- microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care 26: 338-342.
23. Kim SS, Song SH, Kim IJ, Yang JY, Lee JG, et al. (2012) Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diabetes Res Clin Pract 97: 251-257.
24. Fu WJ, Li BL, Wang SB, Chen ML, Deng RT, et al. (2012) Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration. Diabetes Res Clin Pract 95: 105-109.
25. Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, et al. (2011) Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-Acetyl-b- D-glucosaminidase. Kidney Int 79: 464-470.
26. Thallas-Bonke V, Coughlan MT, Tan AL, Harcourt BE, Morgan PE, et al. (2013) Targeting the AGE - RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. Nephrology (Carlton) 18: 47-56.
27. Alter ML, Kretchmer A, von Websky K, Tsuprykov O, Reichetzeder C, et al. (2012) Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab 58: 659-671.
28. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Mioshi H, et al. (1999) Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by novel advanced glycation end product inhibitor, OPB - 9195. Diabetologia 42: 579-588.
29. Cohen MP, Chen S, Ziyadeh FN, Shea E, Hud EA, et al. (2005) Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy. Kidney Int 68: 1554-1561.
30. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, et al. (2003) Nephrin expression is reduced in human diabetic nephropathy. Evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52: 1023-1030.
31. Nauta FL, Boertien WE, Bakker SJ, van Goor H, van Oeveren W, et al. (2011) Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 34: 975-981.
32. Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL Jr, et al. (2010) Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 53: 49-57.
33. Kravaritou M, Thanopoulou A, Karamanos B, Kofinis A, Noutsou M, et al. (2009) Evidence that even ''normal'' albuminuria may denote incipient eGFR reduction in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 85: 317-321.
34. Borges RL, Hirota AH, Quinto BM, Ribeiro AB, Zanella MT, et al. (2010) Is cystatin C a useful marker in the detection of diabetic kidney disease? Nephron Clin Pract 114: c127-c134.
35. Jeon YK, Kim MR, Huh JE, Mok JY, Song SH, et al. (2011) Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci 26: 258-263.
36. Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ (2009) Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol 5: 397-406.